Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19357539 | 0.87 | FFAR3 (0.37) | FFAR3ALDH1A1TSHR | |
| SCHEMBL3923583 | 0.87 | FFAR3 (0.37) | FFAR3ALDH1A1TSHR | |
| SCHEMBL19357480 | 0.83 | — | — | |
| SCHEMBL19357481 | 0.83 | — | — | |
| SCHEMBL7548122 | 0.83 | GRIK1 (0.35) | GRIK1GRIA4GRIK3GRIK5ALDH1A1 | |
| SCHEMBL7545293 | 0.83 | CES1 (0.39) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8673175 | 0.82 | AKR1B1 (0.43) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8673179 | 0.82 | AKR1B1 (0.43) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8600596 | 0.81 | HDAC3 (0.40) | FFAR3ALDH1A1TSHRTDP1 | |
| SCHEMBL540776 | 0.80 | GPR84 (0.45) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110241-A1 | METHOD FOR PRODUCING 1,1,2-TRISUBSTITUTED ETHANE AND METHOD FOR PRODUCING 1,1-DISUBSTITUTED OLEFIN | 東亞合成株式会社 | 2025-05-30 | — | — | WO | disclosed |
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4486739-A1 | MODULATORS OF ACKR3 AND USES THEREOF | InterAx Biotech AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | UTI LIMITED PARTNERSHIP (CA) | 2024-08-22 | — | — | US | disclosed |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DUKE UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2023166190-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| CN-110911750-B | High-voltage lithium ion battery electrolyte, additive and preparation method of additive | 珠海市赛纬电子材料股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20210155627-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | UTI LIMITED PARTNERSHIP (CA) | 2021-05-27 | — | — | US | disclosed |
| US-10934291-B2 | Kinase inhibitors and related methods of use | DUKE UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| CN-110911750-A | High-voltage lithium ion battery electrolyte, additive and preparation method of additive | 珠海市赛纬电子材料股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| EP-1832596-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1483442-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1436371-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003061550-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
| US-4167568-A | TREATMENT OF RESPIRATORY SYSTEM DISORDERS, ANTIHISTAMINES | MAY & BAKER LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | DAPK2, DAPK1, DAPK3 | FFAR3 3656/4885GRIK1 1637/4885GRIA4 3539/4885 |
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | ACKR3, PROKR2, PROKR1 | FFAR3 82/4885GRIK1 407/4885GRIA4 1115/4885 |
| US-10934291-B2 | Kinase inhibitors and related methods of use | DAPK2, DAPK1, DAPK3 | FFAR3 3656/4885GRIK1 1637/4885GRIA4 3539/4885 |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DAPK2, DAPK1, DAPK3 | FFAR3 3656/4885GRIK1 1637/4885GRIA4 3539/4885 |
| US-20210155627-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | DAPK2, DAPK1, DAPK3 | FFAR3 3656/4885GRIK1 1637/4885GRIA4 3539/4885 |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | FFAR3 657/4885GRIK1 1254/4885GRIA4 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.